PSTI Pluristem Therapeutics, Inc.

1.56
-0.02  -1.27%
Previous Close 1.58
Open 1.57
Price To book 3.88
Market Cap 126.39M
Shares 81,020,000
Volume 93,299
Short Ratio 9.57
Av. Daily Volume 113,795

SEC filingsSee all SEC filings

  1. 8-K - Current report 17522298
  2. 8-K - Current report 162067906
  3. 8-K - Current report 162060771
  4. 8-K - Current report 161987152
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161978138

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment to commence 1H 2017.
PLX-PAD (stem cells)
Critical limb ischemia (CLI)
Phase 2 put on clinical hold Jun 2013. Lifted Sept 2013. Enrollment completed May 2016. Data are due late 2017.
PLX-PAD (stem cells)
Intermittent claudication, or IC

Latest News

  1. Pluristem (PSTI) Intermittent Claudication Study Enrolled
  2. Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication
  3. Pluristem Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PSTI-US : January 12, 2017
  4. Pluristem Therapeutics Inc. (PSTI) To Begin CLI Phase III Trial Enrolling Only 250 Patients, With FDA Blessing
  5. PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Other Events
  6. Pluristem shares jump 5.4% premarket as FDA approves trial of treatment for critical limb ischemia
  7. Pluristem’s Phase III Study of PLX-PAD Cells for the Treatment of Critical Limb Ischemia Cleared by U.S. FDA
  8. Pluristem and New York Blood Center to Collaborate in Evaluating PLX-R18 as an Adjuvant Therapy to Umbilical Cord Blood Transplantation, Winning $900,000 Funding From BIRD
  9. Pluristem and New York Blood Center to Collaborate in Evaluating PLX-R18 as an Adjuvant Therapy to Umbilical Cord Blood Transplantation, Winning $900,000 Funding From BIRD
  10. PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  11. Pluristem and Innovative Medical Management Co., Ltd. Mutually Agree to Extend the Time to Execute the Definitive Investment Agreements Due to New Chinese Monetary Policy
  12. Pluristem and Innovative Medical Management Co., Ltd. Mutually Agree to Extend the Time to Execute the Definitive Investment Agreements Due to New Chinese Monetary Policy
  13. Pluristem Therapeutics, Inc. – Value Analysis (NASDAQ:PSTI) : December 22, 2016
  14. Pluristem Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PSTI-US : December 21, 2016
  15. PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
  16. Pluristem and Sosei CVC to Establish a New Corporation for the Commercialization of PLX-PAD in Japan
  17. Pluristem and Sosei CVC to Establish a New Corporation for the Commercialization of PLX-PAD in Japan
  18. United States Joins the Accelerated Regulatory Pathways for Regenerative Therapies
  19. United States Congress Passes Bill that Represents a Major Opportunity for Regenerative Therapies

SEC Filings

  1. 8-K - Current report 17522298
  2. 8-K - Current report 162067906
  3. 8-K - Current report 162060771
  4. 8-K - Current report 161987152
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161978138
  6. 8-K - Current report 161950304
  7. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 161873612
  8. S-8 - Securities to be offered to employees in employee benefit plans 161738866
  9. 8-K - Current report 161685992
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 161631742